Biocon Limited, an innovation-led global biopharmaceutical company, announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,500 crore through the issuance of 13, 63, 63,635 equity shares of face value Rs. 5 each to eligible qualified institutional buyers at the issue price of Rs 330 per Equity Share (including a premium of Rs. 325 per Equity Share).

The QIP, which opened on June 16, 2025, and closed on June 19, 2025, witnessed robust investor interest from a diverse group of domestic and international investors, underscoring strong confidence in Biocon’s growth prospects.

Siddharth Mittal, CEO and Managing Director, Biocon Limited, said, "The strong response to our QIP reflects deep investor convictions in Biocon’s differentiated strategy and consistent execution. This capital raise further strengthens our balance sheet, enabling us to invest in innovations, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide.”

The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures issued by our Subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2. It will also be used for the repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued and/or borrowings availed by our Company, and/or meeting other financial commitments of our company; and general corporate purposes.